Frozen people treatment of new hope - the country's first Idala feng injection for ALS listing.

Recently, the State Drug Administration (NMPA) recently approved the Nanjing Xiansheng Dongyuan Pharmaceutical Co., Ltd. must save ® (Ida Lafeng injection, including 5ml:10mg, 20ml:30mg two specifications) new adaptive disorders for the treatment of freezing human disease.
is the world's second and first domestic-listed Idalaven injection, which is expected to help freeze patients live longer and improve their quality of life.
August 28, 2020 Drug approval documents to be received information release (Source: NMPA) September 8, was awarded the "people's hero" national honorary title of hubei Provincial Health Commission deputy director, Wuhan Jinyintan Hospital President Zhang Dingyu hobbled into the Great Hall of the People in Beijing to participate in the national recognition conference against the outbreak of new crown pneumonia.
he was suffering from a "frozen" terminal illness, his wife was infected and isolated, but hidden from the hospital medical staff, led more than 600 white guards rushed in front, with the disease to compete for time.
said, "Sex is urgent because life leaves me little time."
I had to run faster to win the time, and I had to run faster to get more patients out of the virus.
" currently, global treatments for freezing are limited, not only incurable, but also with proven effective drugs.
is known as amyotrophic lateral sclerosis (AMYotrophiclateral Sclerosis, ALS) and has been around for more than 140 years.
there is no effective drug treatment for freezing disease, also known as motor neurone disease, is an incurable disease.
in addition to symptom therapy, ALS still has no medication to effectively change the course of the disease.
2015, Japan and South Korea first approved Ida Raffle for the treatment of ALS, and the FDA approved the treatment of ALS in May 2017 in a six-month clinical trial based on Japan.
22 years since the FDA approved the anti-exciting toxic drug liruzo.
Italafeng was originally used as a brain protector to suppress local cerebral blood flow around infarction in patients with acute cerebral infarction, prevent the progression of cerebral edema and cerebral infarction, relieve neurological symptoms, and inhibit the death of late neurons. The
-factor study suggests that Idalafon can remove free fundamentals and inhibit lipid peroxidation, thereby inhibiting oxidative damage to brain cells, cell vascular endodertic cells, nerve cells, so Idalafon injections are mainly used to improve the neurological symptoms caused by acute cerebral infarction, daily activity and dysfunction.
is safe due to its long-term use in the treatment of acute ischemic stroke.
has laid a foundation for the approval of new adaptations.
as a free-form sculven agent, oxidative stress can be reduced, and oxidative stress is an important factor in the occurrence and progress of ALS.
48-week study of the long-term efficacy of Idalafon's treatment of amyotrophic lateral sclerosis in 2019 was published in the journal MUSCEL and NERVES.
study to better understand the long-term efficacy of Idarafeng in treating patients with acute atrophic lateral sclerosis.
images from: A special analysis in the musCEL and NERVES journal compared the effects of Idala at 48 weeks with a placebo at 24 weeks, Idala at 24 weeks, or with a placebo expected to last from the beginning to 48 weeks.
images from: Long-term edaravone efficacy in amyotrophic lateral sclerosis study showed that over a 48-week study period, a comparison between Idalafon and placebo showed that the ALSFRS-R score of the Ida Lafon treatment group was significantly lower than that of the placebo group.
significant differences between actual Idalafon and placebos were observed in week 24, these results showed that the benefits of Ida lafon compared to placebo were maintained during the 48-week treatment.
, the function of placebo patients who switched to Idalafon at the 24th turn was also lower than in patients who had used a placebo in full at 48 weeks.
The drop slope in the placebo group between weeks 24 and 48 also appears to be similar to that of patients initially randomly assigned to the Idalafon group, indicating the therapeutic benefits of Idalafon in alS patients and potential benefits for patients who may have more disease progression.
the therapeutic effects of Idalafeng may last and last up to a year.
the first Idalaphon injection in China, it means that China's frozen disease patients are expected to get more drugs and treatment possibilities, improve the quality of life, beat the disease to delay progress, extend the survival time.
.